<DOC>
	<DOCNO>NCT02443155</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial assess clinical proof-of-principle NNC0114-0006 liraglutide preservation beta-cell function adult subject newly diagnose type 1 diabetes mellitus .</brief_summary>
	<brief_title>A Clinical Proof-of-principle Trial Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating Effect NNC0114-0006 Liraglutide Preservation Beta-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial T1DM ( type 1 diabetes mellitus ) ( diagnose clinically ) 12 week prior Randomisation Male female , age 1845 ( inclusive ) time sign informed consent form Nonfasting Cpeptide high equal 0.2 nmol/l BMI ( body mass index ) high equal 18.5 kg/m^2 Presence one islet specific auto antibody ( glutamic acid decarboxylase ( GAD ) , islet antigen2 ( IA2 ) zinctransporter 8 ( ZnT8 ) ) screen Insulin dependence unless temporary spontaneous remission ( honeymoon period ) Daily insulin usage 1 U/kg per day screening use continuous subcutaneous insulin infusion ( CSII ) History recurrent ( e.g . several time year ) severe ( e.g . pneumonia ) chronic infection condition predispose chronic infection ( e.g. , bronchiectasis chronic osteomyelitis ) History severe systemic fungal infection within past 12 month prior screen unless treat resolved appropriate document therapy Vaccination within 4 week randomisation , Visit 3 ( V3 ) Receipt concomitant medication herbal product influence immune system within 90 day prior screen ( V1 ) History pancreatitis ( acute chronic ) Family personal history Multiple Endocrine Neoplasia Type 2 ( MEN2 ) Medullary Thyroid Carcinoma ( MTC ) Any past current diagnosis malignant neoplasm Known impairment immune system , except T1DM</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>